Detection of Plasma Circulating Tumor DNA in Gastric Cancer
NCT ID: NCT05027347
Last Updated: 2022-04-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2021-10-10
2023-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Monitoring Minimal Residual Disease in Gastric Cancer by Liquid Biopsy Study Description
NCT05029869
Detection of CTC and ctDNA in the Diagnosis of Metastasis in Gastric Cancer
NCT05208372
Early Detection of Gastric Cancer Using Plasma Cell-free DNA Fragmentomics
NCT05269056
Multi-Omics Noninvasive Inspection of TumOr Risk for Gastric Cancer
NCT04947995
Early Detection of Five Common Cancers Using the ctDNA Analysing Test
NCT05227261
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
100 healthy people
10 ml blood and tissue biopsy were collected from each patient
plasma circulating tumor DNA
A liquid biopsy assay for identification of tumor derived mutations in plasma of gastric cancer
100 gastric cancer patients
10 ml blood and tissue biopsy were collected from each patient
plasma circulating tumor DNA
A liquid biopsy assay for identification of tumor derived mutations in plasma of gastric cancer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
plasma circulating tumor DNA
A liquid biopsy assay for identification of tumor derived mutations in plasma of gastric cancer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Histologically proven stage (I, II and IIIA) gastric adenocarcinoma
3. Naivety to treatment.
4. No known other concomitant cancer diagnosis
5. Signed informed consent
Exclusion Criteria
2. Underwent any type of treatment
3. Unable to undergo biopsy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Center Ho Chi Minh City (UMC)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medical Center Ho Chi Minh City
Ho Chi Minh City, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
79/GCN-HDDD 2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.